AAN unveils new guidelines for MS disease-modifying therapy

Nat Rev Neurol. 2018 Jul;14(7):384-386. doi: 10.1038/s41582-018-0026-7.

Authors

Stefan Bittner¹, Frauke Zipp²

Affiliations

¹ Department of Neurology, Focus Program Translational Neurosciences and Immunotherapy, Rhine-Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
² Department of Neurology, Focus Program Translational Neurosciences and Immunotherapy, Rhine-Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. [email protected].

PMID: 29895963
DOI: 10.1038/s41582-018-0026-7

No abstract available

Publication types

News

MeSH terms

Humans
Immunologic Factors / administration & dosage*
Immunologic Factors / adverse effects
Multiple Sclerosis / drug therapy*
Neurology / standards
Practice Guidelines as Topic* / standards
Societies, Medical / standards

Substances

Immunologic Factors